
Apo(a) isoform size affects Lp(a) response to lipid lowering therapy
January 15, 2025
People with larger apo(a) size have the greatest reduction in Lp(a) level in response to potent lipid lowering therapy (LLT). This was one of the findings from the Phase 4 CHOlesterol Reduction and Residual Risk in Diabetes (CHORD) study in which participants with LDL-C >100 mg/dL with and without diabetes (DM) received LLT for 30 […]